{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:41Z","timestamp":1786982381715,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12325-023-02738-0","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T22:02:16Z","timestamp":1702936936000},"page":"696-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparative Effectiveness of Teclistamab Versus Real-World Physician\u2019s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"41","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Esther","family":"Gonzalez Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lindsey-Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ghilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Strulev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im\u00e8ne","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slavcev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"1","key":"2738_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-022-05058-5","volume":"102","author":"B Tanenbaum","year":"2023","unstructured":"Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed\/refractory multiple myeloma. Ann Hematol. 2023;102(1):1\u201311. https:\/\/doi.org\/10.1007\/s00277-022-05058-5.","journal-title":"Ann Hematol"},{"key":"2738_CR2","doi-asserted-by":"publisher","first-page":"204062071882266","DOI":"10.1177\/2040620718822660","volume":"10","author":"LE Franssen","year":"2019","unstructured":"Franssen LE, Mutis T, Lokhorst HM, van de Donk N. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:2040620718822660. https:\/\/doi.org\/10.1177\/2040620718822660.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2738_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000528","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528. https:\/\/doi.org\/10.1097\/hs9.0000000000000528.","journal-title":"Hemasphere"},{"issue":"3","key":"2738_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3):26. https:\/\/doi.org\/10.1038\/s41408-018-0065-8.","journal-title":"Blood Cancer J"},{"key":"2738_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100808","volume":"49","author":"K Ramasamy","year":"2021","unstructured":"Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49:100808. https:\/\/doi.org\/10.1016\/j.blre.2021.100808.","journal-title":"Blood Rev"},{"issue":"1","key":"2738_CR6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087. https:\/\/doi.org\/10.1186\/s12885-020-07503-y.","journal-title":"BMC Cancer"},{"issue":"5","key":"2738_CR7","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136. https:\/\/doi.org\/10.1038\/s41375-022-01531-2.","journal-title":"Leukemia"},{"issue":"9","key":"2738_CR8","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375. https:\/\/doi.org\/10.1038\/s41375-019-0435-7.","journal-title":"Leukemia"},{"key":"2738_CR9","unstructured":"ABECMA (idecabtagene vicleucel). Package insert. Bristol-Myers Squibb Company; 2021."},{"key":"2738_CR10","unstructured":"ABECMA (idecabtagene vicleucel). Summary of product characteristics. Celgene Distribution BV; 2021."},{"key":"2738_CR11","unstructured":"CARVYKTI (ciltacabtagene autoleucel). Janssen Biologics BV; 2022."},{"key":"2738_CR12","unstructured":"CARVYKTI (ciltacabtagene autoleucel). Package insert. Janssen Biotech, Inc.; 2022."},{"issue":"6","key":"2738_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/jco.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374. https:\/\/doi.org\/10.1200\/jco.22.00842.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2738_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"6","key":"2738_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"issue":"24","key":"2738_CR16","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"issue":"9","key":"2738_CR17","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase\u00a02 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.\u00a0https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"2738_CR18","unstructured":"TECVAYLI (teclistamab-cqyv). Package insert. Janssen Biotech, Inc; 2022."},{"key":"2738_CR19","unstructured":"TECVAYLI (teclistamab). Summary of product characteristics. Janssen Biologics BV; 2022."},{"key":"2738_CR20","unstructured":"ELREXFIO (elranatamab-bcmm). Package insert. Pfizer, Inc; 2023."},{"key":"2738_CR21","unstructured":"TALVEY (talquetamab-tgvs). Package insert. Janssen Biotech, Inc; 2023."},{"key":"2738_CR22","unstructured":"TALVEY (talquetamab). Summary of product characteristics. Janssen Biologics BV; 2023."},{"key":"2738_CR23","unstructured":"NEXPOVIO (selinexor). Summary of product characteristics. Stemline Therapeutics BV; 2021."},{"key":"2738_CR24","unstructured":"XPOVIO (selinexor). Package insert. Karyopharm Therapeutics; 2019."},{"issue":"8","key":"2738_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1903455.","journal-title":"N Engl J Med"},{"key":"2738_CR26","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ. Long-term follow-up from MajesTEC-1 of teclistamab, a BCMA\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2\u20136, 2023; Chicago, IL, USA & Virtual.","DOI":"10.1016\/S2152-2650(23)01411-8"},{"issue":"5","key":"2738_CR27","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","volume":"40","author":"P Moreau","year":"2023","unstructured":"Moreau P, van de Donk N, Delforge M, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective locommotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther. 2023;40(5):2412\u201325. https:\/\/doi.org\/10.1007\/s12325-023-02480-7.","journal-title":"Adv Ther"},{"issue":"12","key":"2738_CR28","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486\u201394. https:\/\/doi.org\/10.1002\/ajh.25963.","journal-title":"Am J Hematol"},{"key":"2738_CR29","unstructured":"Mateos MV. Comparative effectiveness of teclistamab vs real-world physician\u2019s choice of therapy in the locomotion and moment studies for patients with triple-class exposed relapsed\/refractory multiple myeloma. In: Presented at the 20th International Myeloma Society (IMS) Annual Meeting; September 27\u201330, 2023; Athens, Greece."},{"key":"2738_CR30","doi-asserted-by":"crossref","unstructured":"Weisel K. Standard of care outcomes in the last 3\u00a0years in patients with triple-class exposed relapsed\/refractory multiple myeloma: the first pooled analysis of LocoMMotion and MoMMent Trials. The 20th International Myeloma Society (IMS) Annual Meeting; September 27\u201330, 2023; Athens, Greece.","DOI":"10.1016\/S2152-2650(23)01943-2"},{"issue":"8","key":"2738_CR31","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"521","key":"2738_CR32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390\u2013400. https:\/\/doi.org\/10.1080\/01621459.2016.1260466.","journal-title":"J Am Stat Assoc"},{"issue":"25","key":"2738_CR33","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"key":"2738_CR34","unstructured":"Moreau P. LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed\/refractory multiple myeloma\u2014final analysis at 2-year follow-up. In: Presented at the European Hematology Association (EHA) 2023 Hybrid Congress; June 8\u201311, 2023; Frankfurt, Germany."},{"issue":"4","key":"2738_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417\u201328. https:\/\/doi.org\/10.1016\/j.jval.2011.04.002.","journal-title":"Value Health"},{"issue":"2","key":"2738_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989x17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200\u201311. https:\/\/doi.org\/10.1177\/0272989x17725740.","journal-title":"Med Decis Mak"},{"issue":"Suppl 2","key":"2738_CR37","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2023;98(Suppl 2):S13\u2013S21. https:\/\/doi.org\/10.1002\/ajh.26628.","journal-title":"Am J Hematol"},{"key":"2738_CR38","unstructured":"Myeloma UK Selinexor Horizons Infosheet. https:\/\/www.myeloma.org.uk\/library\/selinexor-infosheet\/. Accessed Aug 7, 2023."},{"key":"2738_CR39","unstructured":"BLENREP (belantamab mafodotin-blmf). Summary of product characteristics. GlaxoSmithKline Manufacturing SpA; 2020."},{"key":"2738_CR40","unstructured":"GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation. 2022. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation. Accessed Sept 20, 2023."},{"key":"2738_CR41","unstructured":"EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. 2023. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep. Accessed Sept 19, 2023."},{"issue":"4","key":"2738_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","volume":"29","author":"T Kourelis","year":"2023","unstructured":"Kourelis T, Bansal R, Berdeja J, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T\u00a0cell slot allocation: a multi-institution experience. Transplant Cell Ther. 2023;29(4):255\u20138. https:\/\/doi.org\/10.1016\/j.jtct.2023.01.012.","journal-title":"Transplant Cell Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02738-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02738-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02738-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:18:22Z","timestamp":1707005902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02738-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2738"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02738-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philippe Moreau: served in a consulting\/advisory role and has received honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Oncopeptides and Sanofi. Mar\u00eda-Victoria Mateos: served in a consulting\/advisory role for AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Regeneron, Roche\/Genentech, and Takeda; and has received honoraria from AbbVie\/Genentech, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda. Maria Esther Gonzalez Garcia: no conflicts of interest to disclose. Hermann Einsele: received research funding or honoraria from and has served as a consultant or adviser for Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen and Sanofi. Valerio De Stefano: served on an advisory board or speakers\u2019 bureau and received honoraria from AbbVie, Alexion, Amgen, AOP Health, Argenx, Bristol Myers Squibb, Grifols, GlaxoSmithKline, Leo Pharma, Novartis, Novo Nordisk, Sanofi, SOBI and Takeda. Lionel Karlin: has served in a consulting\/advisory role for Amgen, Janssen, Celgene\/Bristol Myers Squibb, GlaxoSmithKline, Sanofi, Stemline, Takeda and AbbVie; received honoraria from AbbVie, Amgen, Celgene\/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, Stemline and Takeda; has received travel expenses from Amgen, Celgene\/Bristol Myers Squibb, Janssen, Sanofi and Takeda; and has an immediate family member employed by Laboratoire Aguettant. Joanne Lindsey-Hill: has received consulting fees from AbbVie and received travel expenses from Janssen. Britta Besemer: received travel, accommodations, and expenses and received honoraria from Amgen, GlaxoSmithKline and Janssen-Cilag. Laure Vincent: received funding from Janssen; received honoraria for consulting\/advisory role from Bristol Myers Squibb and Janssen; received travel expenses from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi and Takeda;\u00a0and has participated in a Data Safety Monitoring Board or Advisory Board for Bristol Myers Squibb, Janssen and Takeda. Suriya Kirkpatrick: received honoraria from Celgene\/Bristol Myers Squibb; received travel expenses from AbbVie, Celgene\/Bristol Myers Squibb and Janssen; participated in a Data Safety Monitoring Board or Advisory Board for Celgene; and served in a leadership or fiduciary role for UKONS Research MIG and UK Lung Cancer Nurses RIG. Michel Delforge: served in a consulting\/advisory role for Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, Stemline and Takeda; and has received research funding from Janssen. Aurore Perrot: served in a consulting role and received honoraria from AbbVie, Amgen, Celgene, Janssen-Cilag, Pfizer, Sanofi and Takeda. Niels\u00a0W.C.J. van de Donk: served in a consulting\/advisory role for AbbVie, Adaptive Biotechnologies, Amgen, Bayer, Bristol Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, Servier and Takeda; and has received research funding from Amgen, Bristol Myers Squibb, Celgene, Cellectis, Janssen and Novartis. Charlotte Pawlyn: received honoraria from AbbVie, Amgen, Celgene\/Bristol Myers Squibb, Janssen, Pfizer, Sanofi and Takeda. Salomon Manier: received research funding from AbbVie, Celgene\/Bristol Myers Squibb, Janssen, Novartis and Takeda. Xavier Leleu: held a consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb, CARsgen, Celgene, Gilead, GlaxoSmithKline, Janssen-Cilag, Karyopharm, Merck, Novartis, Oncopeptides, Roche and Takeda; received travel, accommodations and\/or expenses from Takeda; and received honoraria from AbbVie, Amgen, Bristol Myers Squibb, CARsgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm, Merck, Novartis, Oncopeptides, Roche, Sanofi and Takeda. Joaquin Martinez-Lopez: has served in a consulting or advisory role, received speakers\u2019 bureau fees and research funding from Bristol Myers Squibb, Janssen and Novartis. Francesca Ghilotti, Joris Diels, Ra\u00fal Morano, Im\u00e8ne Haddad, Lixia Pei, Rachel Kobos, Jennifer Smit, Mary Slavcev and Alexander Marshall: employed by Janssen. Claire Albrecht and Vadim Strulev: employed by and own stock in Janssen. Katja Weisel: served as a consultant for and received honoraria from Adaptive Biotechnologies, Karyopharm and Takeda; has received honoraria from Roche; and has received honoraria and served as a member on boards of directors and\/or advisory committees for Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncopeptide and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data analyzed in this study were received from the MajesTEC-1, LocoMMotion, and MoMMent studies. MajesTEC-1 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. An independent ethics committee or institutional review board at each study center approved the study protocol. The LocoMMotion and MoMMent studies were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. An independent ethics committee\/institutional review board at each center approved the study protocol, listed in the Supplementary Material.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}